📇 Rhumatologue · VANNES · (56) · Mixte
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
5 raisons identifiées
Praticien-chercheur
6 articles scientifiques publiés — formation continue solide
Cabinet de groupe — continuité de soins
Plusieurs praticiens dans le même cabinet — un confrère peut prendre le relais en cas d'absence
Référence presse grand public
Cité 1 fois dans les médias — pédagogie reconnue
Disponibilité géographique
3 lieux d'exercice — choisissez celui qui vous arrange
Délais de RDV courts dans la région
141.3 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
SELARL DOCTEUR PRUVOST-BALLAND
7 RUE GENEVIEVE DE GAULLE ANTHONIOZ, 56000 VANNES
CDS SABOURAUD
PAVILLON BIET 2 PL DR ALFRED FOURNIER, 75010 PARIS
CHRU RENNES SITE PONTCHAILLOU
PONTCHAILLOU 2 R HENRI LE GUILLOUX, 35000 RENNES
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Source : Google News (recherche par nom complet — homonymes possibles, vérifier le contenu).
📰 Ouest-France · 04/02/2023
<a href="https://news.google.com/rss/articles/CBMi3gFBVV95cUxPOFZpendtbE8yalpFNjN0T3VXRUh2RVJCU0tKSFlIOENqT0JYNi1jc2hvb2pGcWJJbHJBeGc5WUVzc2VlaW44UUU2MzVUY1FXVEdnYmE3dzBfak0zRzVraHlSYWdDUW44T3U3Nnc4WEVIRnVTX1N4T1hqNjRZaTN3WmtPZjVKdEVxSUlYZHFWMkZPTkVlNGZjVzB5bFRYSlhuUjlJa2V4VER6VlA4Q1RGQ0FZZWd3MVRScH
Journal of medical genetics · 2011
Background Hereditary leiomyomatosis and renal cell cancer (HLRCC) is an autosomal dominant disorder predisposing humans to cutaneous and uterine leiomyomas; in 20% of affected families, type 2 papillary renal cell cancers (PRCCII) also occur with aggressive course and poor prognosis. HLRCC results from heterozygous germline mutations in the tumour suppressor fumarate hydratase (FH) gene. Methods As part of the French National Cancer Institute (INCa) ‘Inherited predispositions to kidney cancer’ network, sequence analysis and a functional study of FH were preformed in 56 families with clinically proven or suspected HLRCC and in 23 patients with isolated PRCCII (5 familial and 18 sporadic). Results The study identified 32 different germline FH mutations (15 missense, 6 frameshifts, 4 nonsense, 1 deletion/insertion, 5 splice site, and 1 complete deletion) in 40/56 (71.4%) families with proven or suspected HLRCC and in 4/23 (17.4%) probands with PRCCII alone, including 2 sporadic cases. 21 of these were novel and all were demonstrated as deleterious by significant reduction of FH enzymatic activity. In addition, 5 asymptomatic parents in 3 families were confirmed as carrying disease-causing mutations. Conclusions This study identified and characterised 21 novel FH mutations and demonstrated that PRCCII can be the only one manifestation of HLRCC. Due to the incomplete penetrance of HLRCC, the authors propose to extend the FH mutation analysis to every patient with PRCCII occurring before 40 years of age or when renal tumour harbours characteristic histologic features, in order to discover previously ignored HLRCC affected families.
Clinical and experimental dermatology · 2023
Abstract Although retinoids are considered as the most effective treatment, management of dissecting cellulitis of the scalp (DCS) is often challenging. A multicentre retrospective study was conducted to evaluate the efficacy of anti-tumour necrosis factor (TNF) agents in treating DCS after failure of other conventional treatments. Twenty-six patients were included. After a mean treatment duration of 19 months (SD 21), the median Physician’s Global Assessment score decreased from 3 to 1. The median number of inflammatory nodules and abscesses decreased from 7 to 0.5 and from 1 to 0, respectively. The median Dermatology Life Quality Index and numerical rating scale score for pain severity decreased from 10 to 8 and 6 to 1, respectively. The median treatment satisfaction was 7 out of 10 on the Patient Satisfaction Index. This study confirms the efficacy of anti-TNF agents in treating patients with DCS that is resistant to conventional therapies.
JAMA dermatology · 2025
This cohort study investigates the potential therapeutic benefits of glucagon-like peptide-1 receptor agonists in patients with hidradenitis suppurativa.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Journal of the European Academy of Dermatology and Venereology : JEADV · 2026 · Letter
Cogrel O, Reybet-Degat P, Hotz C, Richard-Lallemand MA, et al.
JAMA dermatology · 2025 · Journal Article
Gouvrion L, Delage M, Villani AP, Le Naour S, et al.
Clinical, cosmetic and investigational dermatology · 2024 · Journal Article
Ezanno AC, Fougerousse AC, Pruvost-Balland C, Maccari F, et al.
Clinical and experimental dermatology · 2023 · Multicenter Study
Alzahrani M, Coste V, Konstantinou MP, Reguiai Z, et al.
Journal of medical genetics · 2011 · Journal Article
Gardie B, Remenieras A, Kattygnarath D, Bombled J, et al.
Journal of the American Academy of Dermatology · 2026 · Journal Article
Reguiai Z, Fougerousse AC, Bachelez H, Fredeau L, et al.